Phaseline

Targets › CYP4V2

CYP4V2 (Cytochrome P450 4V2): drug programs, companies and trials

3 programs from 3 companies in 5 trials: 3 Phase 1, 2 Phase 3; Ophthalmology; next expected readout Dec 2026.

A cytochrome P450 monooxygenase involved in fatty acid metabolism in the eye. Catalyzes the omega-hydroxylation of polyunsaturated fatty acids (PUFAs) docosahexaenoate (DHA) and its precursor eicosapentaenoate (EPA), and may contribute to the homeostasis of these retinal PUFAs. (UniProt, Q6ZWL3)

Open in Phaseline: the race on CYP4V2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Vitalgen BioPharmaVGR-R01
CYP4V2-coding gene delivered by AAV vector
CYP4V2Phase 3Bietti Crystalline DystrophyDec 2026
Chigenovo Co., LtdZVS101e
AAV8-delivered CYP4V2 gene therapy
CYP4V2Phase 3Bietti Crystalline Corneoretinal Dystrophy; Bietti's Crystalline DystrophyDec 2028
NGGT (Suzhou) BiotechnologyNGGT001
AAV-mediated CYP4V2 gene delivery via subretinal injection
CYP4V2Phase 1Bietti Crystalline Corneoretinal DystrophySep 2029

Conditions

Bietti Crystalline Corneoretinal Dystrophy (2) Bietti Crystalline Dystrophy (2) Bietti's Crystalline Dystrophy (1)

Modalities

other (1), protein or peptide (1), small molecule (1)

Companies

Chigenovo Co., Ltd (1) NGGT (Suzhou) Biotechnology (1) Shanghai Vitalgen BioPharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.